Baidu Shares Surge After Official Launch of Advanced Ernie 5.0 AI Model 
JPMorgan and Allen & Company Emerge as Big Winners in Warner Bros Discovery Bidding War 
Apple Stock Jumps as Company Prepares Major Siri AI Chatbot Upgrade 
Court Allows Expert Testimony Linking Johnson & Johnson Talc Products to Ovarian Cancer 
Pop Mart Shares Surge in Hong Kong After First Buyback in Nearly Two Years 
Valentino Garavani Dies at 93, Leaving Behind the Timeless Legacy of Valentino Red 
Walmart to Cut PhonePe Stake in IPO as Tiger Global and Microsoft Exit 
United Airlines Posts Record Q4 Revenue as Premium Demand Lifts Earnings 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
Lynas Rare Earths Shares Surge as Quarterly Revenue Jumps on Strong Prices 
Apple China Holiday Sale Offers Discounts Up to 1,000 Yuan on Popular Devices 
FSU Criticizes ANZ Over Suncorp Bank Job Cuts Amid Post-Acquisition Commitments 
Trump Signs Executive Order to Limit Wall Street Investment in Single-Family Homes 
Brazil Supreme Court Orders Asset Freeze of Nelson Tanure Amid Banco Master Investigation 
Nvidia CEO Jensen Huang Plans China Visit Amid AI Chip Market Uncertainty 
BHP Posts Record Iron Ore Output as China Pricing Pressures Loom 
DURHAM, N.C., May 02, 2017 -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients, today announced that it will host a live conference call and audio webcast on Tuesday, May 9, 2017 at 8:30 a.m. ET to report financial results for the first quarter ended March 31, 2017, and to provide a business overview.
To access the live conference call, please dial (877) 354-4056 (domestic) or (678) 809-1043 (international) at least five minutes prior to the start time, and refer to conference ID 3258363. A live audio webcast of the call will also be available on the Investors’ section of the Company's website, www.chimerix.com. An archived webcast will be available on the Chimerix website approximately two hours after the event.
About Chimerix
Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients. Chimerix's proprietary lipid conjugate technology has produced brincidofovir (BCV); CMX157, which was licensed to ContraVir Pharmaceuticals; and earlier-stage clinical candidates. Chimerix recently announced a new clinical candidate, CMX521, for the treatment and/or prevention of norovirus. For further information, please visit Chimerix's website, www.chimerix.com.
CONTACT: Investor Relations: [email protected] or Will O’Connor Stern Investor Relations [email protected] 212-362-1200 Media: Becky Vonsiatsky W2O Group [email protected] 413-478-2003
